INC Research spells out details on $150M IPO

INC Research has spelled out its IPO plans, looking to raise $150 million through the sale of 8.1 million shares at $17 to $20 a share. Renaissance Capital reports that at the midpoint of that range, INC would be left with a market cap of $1.1 billion. A number of CROs have been going public this year as improved sentiment for biotech has kept the IPO window in the industry open for two years now. INC will be hoping that investors look past some turbulence in the market to embrace the company. Story

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.